Detalhes bibliográficos
| Ano de defesa: |
2022 |
| Autor(a) principal: |
Souza, Débora Naomi de |
| Orientador(a): |
Mezan, Renato
 |
| Banca de defesa: |
Não Informado pela instituição |
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Pontifícia Universidade Católica de São Paulo
|
| Programa de Pós-Graduação: |
Programa de Estudos Pós-Graduados em Psicologia: Psicologia Clínica
|
| Departamento: |
Faculdade de Ciências Humanas e da Saúde
|
| País: |
Brasil
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
https://repositorio.pucsp.br/jspui/handle/handle/29525
|
Resumo: |
In view of the developments in neuroscience research and the successive synthesis of new psychotropic drugs, there is currently a progressive increase in the number of patients undergoing psychoanalitic follow-up who use some psychotropic medication. In this way, the objective of the present study is to demonstrate that psychoanalysis and psychopharmacology can be compatible, taking a brief tour of Freudian psychopathology through clinical fragments of analyzes of patients who received concomitant psychotropic medications. The point of view chosen in this relationship – psychopharmacology and psychoanalysis – will be from the place of psychopharmacology in psychoanalysis. Basically, two assumptions are contained in this study: 1) The neurobiological theories that support the use of psychotropic drugs in the treatment of mental disorders today and the psychoanalytic theories are not necessarily exclusive, if we consider that both have different purposes, diagnostic and investigation methods. 2) The relationship between psychopharmacology and psychoanalysis can be one of mutual collaboration, insofar as the use of psychotropic medications in the psychoanalytic context has been shown to reduce symptoms that could make the work of analysis difficult or even impossible. In order to achieve the proposed objective, some previous considerations and reflections are necessary. Thus, in the first chapter of the present study, the history of modern psychopharmacology will be described – notably the history that led to the discovery of the antipsychotic effects of chlorpromazine in 1952 -, as well as a presentation of contemporary psychiatry. Considering that the development of neurobiological theories of mental disorders is closely related to the use of psychotropic substances, in the second chapter will be discussed the relationship between psychoanalysis and neurosciences |
